Impact of the Covid-19 on RSV
IPCoVRS-2
Impact of the Covid-19 Pandemic on the Epidemiology of Respiratory Syncytial Virus
1 other identifier
observational
600
1 country
2
Brief Summary
The magnitude of seasonal RSV epidemics brings each year new logistical challenges for the hospitalization of young infants with bronchiolitis that overwhelm hospital capacities and lead to specific winter plans with deprogramming and mobilization of human and logistical resources. The Covid-19 pandemic has changed the way winter epidemics are presented. For example, the seasonal RSV epidemic was shifted by several months in Lyon, with an impression of a lower incidence of hospitalized cases, with a population of older children and with fewer signs of clinical severity. This is largely attributable to the widespread use of barrier gestures and social distancing measures, known as "non-pharmacological interventions" or NPI. Given the magnitude of the reduction of the RSV epidemic, it is legitimate to analyze the benefits of NPIs to draw lessons for maintaining preventive measures around RSV-vulnerable populations; moreover, new preventive pharmacological interventions are soon to be marketed, whether they are particularly refined and long half-life anti-RSV monoclonal antibodies, RSV vaccines for mothers or for newborns and infants. In this perspective, it is crucial to properly define the populations at risk of severe disease to establish a legitimate hierarchy in the implementation of different preventive strategies. The study of the RSV epidemic is a high potential model because of the convergence of epidemiological, virological, and pharmacological knowledge. However, the study of the impact of the pandemic on the epidemiology of rhinovirus also seems promising because, for reasons unknown to date, it seems that the pandemic did not have the same reducing impact on the rhinovirus epidemic; in the latter case, the interest is to confirm the resistance of this virus and to look for more fundamental explanations, for example, on viral interactions. On a previous study (see NTC 04944160), 519 infants and children were recruited in the Pre-Covid-19 season population, and 277 infants and children were recruited in the first Per-Covid-19 season population. In the present study, the objective is to assess the epidemiology of RVS in infants from the birth cohorts of the tertiary teaching hospitals of Lyon, France, during the Pre-Covid-19 (2013-2020) and the Per-Covid-19 (2020-2025) years.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2022
Typical duration for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 26, 2022
CompletedFirst Posted
Study publicly available on registry
April 27, 2022
CompletedStudy Start
First participant enrolled
May 1, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2025
CompletedMay 3, 2022
April 1, 2022
3.2 years
April 26, 2022
April 27, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Annual evolution of the number and severity of RSV-infection in hospitalized children during per-Covid-19 epidemic compared to pre-Covid-19 pandemic
Description of number of cases for each clinical picture according to pre-SARS-CoV-2 pandemic and per-SARS-CoV-2 pandemic year.
Day 0
Study Arms (2)
pre Covid-19 cohort
Children hospitalized in the Pediatric Department of the " Hôpital Femme Mère Enfant ", Lyon, France with a RT-PCR positive for RSV during the 2013-2020 winter epidemic
Per-Covid-19 cohort
Children hospitalized in the Pediatric Department of the " Hôpital Femme Mère Enfant ", Lyon, France with a RT-PCR positive for RSV during the 2020-2021, 2021-2022, 2022-2023, 2023-2024 and 2024-2025 epidemics. The need for continuation of the study will be reassessed after each season.
Interventions
To review of medical records to describe diagnosis and severity of the disease.
Eligibility Criteria
: Children hospitalized in the Pediatric Department of the " Hôpital Femme Mère Enfant ", Lyon, France with a RT-PCR positive for RSV
You may qualify if:
- Child hospitalized at " Hôpital Femme Mère Enfant ", Lyon, France
- Positive RSV-PCR
You may not qualify if:
- Parent's refusal to participate
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
Virology Lab
Lyon, 69004, France
Pediatric departement
Lyon, 69500, France
Related Publications (1)
Horvat C, Chauvel C, Casalegno JS, Benchaib M, Ploin D, Nunes MC; VRS Study Group in Lyon. RSV Severe Infection Risk Stratification in a French 5-Year Birth Cohort Using Machine-learning. Pediatr Infect Dis J. 2024 Sep 1;43(9):819-824. doi: 10.1097/INF.0000000000004375. Epub 2024 May 7.
PMID: 38713818DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 26, 2022
First Posted
April 27, 2022
Study Start
May 1, 2022
Primary Completion
July 1, 2025
Study Completion
July 1, 2025
Last Updated
May 3, 2022
Record last verified: 2022-04